Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9323737 | 0.75 | LDHA (0.39) | PPARAKMT2AL3MBTL1GAATHRB | |
| SCHEMBL4821484 | 0.75 | THRB (0.36) | THRB | |
| SCHEMBL4185405 | 0.75 | APP (0.37) | THRB | |
| SCHEMBL19781563 | 0.74 | POLB (0.50) | PKMKMT2AGAANPC1RAB9A | |
| SCHEMBL1235239 | 0.72 | NQO1 (0.58) | PKMGAA | |
| SCHEMBL9145439 | 0.72 | THRB (0.38) | PPARAKMT2AL3MBTL1THRB | |
| 3-Methoxyphenylacetonitrile SCHEMBL103029 | 0.72 | PKM (0.61) | PKMFLT3KMT2AGAANPC1 | |
| SCHEMBL6573779 | 0.71 | PKM (0.40) | PKMFLT3KMT2AL3MBTL1GAA | |
| SCHEMBL28035017 | 0.71 | PKM (0.40) | PKMFLT3KMT2AL3MBTL1GAA | |
| Ethane SCHEMBL11166229 | 0.71 | ACACB (0.40) | PKMKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | ABCC1, OSBP, OSBPL3 | PKM 4730/4885PPARA 4549/4885FLT3 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.